The reduced serum concentrations of -arrestin-1 and -arrestin-2 in pregnancies complicated with gestational diabetes mellitus.

OBJECTIVE

This study aimed to analyze maternal serum -arrestin-1 and -arrestin-2 concentrations in pregnant women complicated with gestational diabetes mellitus (GDM) and compare them with the normoglycemic uncomplicated healthy control group.

METHODS

A prospective case-control study was conducted, including pregnant women complicated with GDM between 15 February 2021, and 31 July 2021. We recorded serum -arrestin-1 and -arrestin-2 concentrations of the participants. Receiver operating characteristic (ROC) curves were used to describe and compare the performance of diagnostics value of variables -arrestin-1, and -arrestin-2.

RESULTS

The mean -arrestin-1 and -arrestin-2 levels were found to be significantly lower in the GDM group (41.0 ± 62.8 ng/mL, and 6.3 ± 9.9 ng/mL) than in the control group (93.1 ± 155.4 ng/mL, and 12.4 ± 17.7, respectively,  < .001). When we analyze the area under the ROC curve (AUC), maternal serum -arrestin-1 and -arrestin-2 levels can be considered a statistically significant parameter for diagnosing GDM. -arrestin-1 had a significant negative correlation with fasting glucose ( = -0.551,  < .001), plasma insulin levels ( = -0.522,  < .001), HOMA-IR ( = -0.566,  < .001), and HbA1C ( = -0.465,  < .001). -arrestin-2 was significantly negatively correlated with fasting glucose ( = -0.537,  < .001), plasma insulin levels ( = -0.515,  < .001), HOMA-IR ( = -0.550,  < .001), and HbA1C ( = -0.479,  < .001).

CONCLUSION

-arrestin 1 and -arrestin 2 could be utilized as biomarkers in the diagnosis of GDM. The novel therapeutic strategies targeting these -arrestins may be designed for the GDM treatment.